A Stoke Therapeutics officer told the SEC about a plan to sell $16K of Stoke Therapeutics shares around Oct 2, 2026. The filing says the shares were acquired as compensation.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 144 — Notice of Proposed Sale of Securities

All the details

Dates, kept separate

Planned sale date: Oct 2, 2026
Reporting period: Not applicable
Notice filed with the SEC: Oct 2, 2026

OfficerPlanned saleShares from pay

Context

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001950047-26-010004
Filed / recorded: Oct 2, 2026, 8:20 PM UTC

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Added to OQRO

Oct 7, 2026, 1:40 PM UTC

Parser

form144-v1

Data quality

Read from the record; company matched by name

Issuer

Stoke Therapeutics, Inc.

Issuer CIK

1623526

Table

Non-derivative (Table I)

Transaction date

—

Shares / units

—

Price per share

—

Shares owned after

—

Ownership form

Direct

Amendment

Around the same time

Jonathan Allan (GENERAL COUNSEL & CORP SEC) sold ~$17K of Stoke Therapeutics

Planned saleFiled 5d ago

Barry Ticho (CHIEF MEDICAL OFFICER) sold ~$27K of Stoke Therapeutics

Planned saleFiled 5d ago

Alexander CumboDirector

Filed 12d ago

40KDerivative units

Traded Sep 23 · filed 2 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record